Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F24%3A00080317" target="_blank" >RIV/65269705:_____/24:00080317 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/24:10489152 RIV/00843989:_____/24:E0111281 RIV/00064165:_____/24:10489152

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S2352302624001480" target="_blank" >https://www.sciencedirect.com/science/article/pii/S2352302624001480</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/S2352-3026(24)00148-0" target="_blank" >10.1016/S2352-3026(24)00148-0</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial

Popis výsledku v původním jazyce

Background Isatuximab is an anti-CD38 monoclonal antibody approved for the treatment of relapsed or refractory multiple myeloma. Previous analyses of the IKEMA trial showed prolonged progression-free survival in patients with this disease who received isatuximab in combination with carfilzomib-dexamethasone as compared with those who received carfilzomib-dexamethasone alone. Herein, we report the analysis of overall survival from the IKEMA trial. Methods This prospective, randomised, open-label, active-controlled, phase 3 study included patients with relapsed or refractory multiple myeloma aged 18 years or older, who had received one to three previous lines of treatment from 69 study centres in 16 countries across North America, South America, Europe, and the Asia-Pacific region. Patients were randomly allocated (3:2) to treatment with either isatuximab plus carfilzomib-dexamethasone (isatuximab group) or carfilzomib-dexamethasone (control group). In the isatuximab group, patients received intravenous isatuximab (10 mg/kg on days 1, 8, 15, and 22 of the first 28-day cycle, and days 1 and 15 of subsequent 28-day cycles). In both treatment groups, intravenous carfilzomib (20 mg/m2 on days 1 and 2 of the first cycle; and 56 mg/m2 on days 8, 9, 15, and 16 of the first cycle, and days 1, 2, 8, 9, 15, and 16 of subsequent cycles) and intravenous or oral dexamethasone (20 mg on days 1, 2, 8, 9, 15, 16, 22, and 23) were administered. The primary endpoint of the trial was progression-free survival, which was reported previously. Treatment continued until progression, unacceptable toxicity, or patient request to discontine. The overall survival analysis reported here was planned to be conducted 3 years after the primary progression-free survival analysis in the intention-to-treat population. Additional analyses were conducted on the secondary endpoints of time to next treatment and second-progression-free survival. Reported p values are non-inferential due to hierarchical testing. This trial is registered with ClinicalTrials.gov (NCT03275285). Findings Between Nov 15, 2017, and March 21, 2019, 302 patients were enrolled and randomly allocated: 179 (59%) to the isatuximab group and 123 (41%) to the control group. 169 (56%) patients were male, 133 (44%) were female, 214 (71%) were White, 50 (17%) were Asian, nine (3%) were Black or African American, and three (1%) were multiracial. At data cutoff for this overall survival analysis (Feb 7, 2023), 79 (44%) overall survival events in the isatuximab group and 59 (48%) in the control group had occurred (median follow-up 56&lt;middle dot&gt;61 months [IQR 54&lt;middle dot&gt;90-58&lt;middle dot&gt;02]). Median overall survival (in months) was not reached (NR; 95% CI 52&lt;middle dot&gt;17-NR) in the isatuximab group and was 50&lt;middle dot&gt;60 months (38&lt;middle dot&gt;93-NR) in the control group (hazard ratio [HR] 0&lt;middle dot&gt;855 [95% CI 0&lt;middle dot&gt;608-1&lt;middle dot&gt;202], nominal one-sided p=0&lt;middle dot&gt;18). Survival probability at 48 months was 59&lt;middle dot&gt;7% (95% CI 52&lt;middle dot&gt;0-66&lt;middle dot&gt;7) in the isatuximab group and 52&lt;middle dot&gt;2% (95% CI 42&lt;middle dot&gt;7-60&lt;middle dot&gt;8) in the control group (based on Kaplan-Meier analysis). Improvements in time to next treatment (HR 0&lt;middle dot&gt;583 [95% CI 0&lt;middle dot&gt;429-0&lt;middle dot&gt;792], nominal one-sided p=0&lt;middle dot&gt;0002) and second-progression-free survival (0&lt;middle dot&gt;663 [0&lt;middle dot&gt;491-0&lt;middle dot&gt;895], nominal one-sided p=0&lt;middle dot&gt;0035) were observed in the isatuximab group. The most common treatment- emergent adverse events were infusion reactions (82 [46%] patients in the isatuximab group and four [3%] in the control group) and upper respiratory tract infections (71 [40%] and 34 [28%], respectively). Discontinuations due to treatment-emergent adverse events were similar between treatment groups (24 [14%] in the isatuximab group and 22 [18%] in the control group), despite an additional 30 weeks of exposure in the isatuximab group. 12 (7%) patients in the isatuximab group and six (5%) patients in the control group had a treatment-related adverse event with a fatal outcome during study treatment. Interpretation At the time of the current analysis, a difference in overall survival could not be detected between the treatment groups, and no new safety signals were observed. Collectively, the evidence suggests that isatuximab plus carfilzomib-dexamethasone is a key treatment for patients with relapsed or refractory multiple myeloma. Funding Sanofi.

Název v anglickém jazyce

Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial

Popis výsledku anglicky

Background Isatuximab is an anti-CD38 monoclonal antibody approved for the treatment of relapsed or refractory multiple myeloma. Previous analyses of the IKEMA trial showed prolonged progression-free survival in patients with this disease who received isatuximab in combination with carfilzomib-dexamethasone as compared with those who received carfilzomib-dexamethasone alone. Herein, we report the analysis of overall survival from the IKEMA trial. Methods This prospective, randomised, open-label, active-controlled, phase 3 study included patients with relapsed or refractory multiple myeloma aged 18 years or older, who had received one to three previous lines of treatment from 69 study centres in 16 countries across North America, South America, Europe, and the Asia-Pacific region. Patients were randomly allocated (3:2) to treatment with either isatuximab plus carfilzomib-dexamethasone (isatuximab group) or carfilzomib-dexamethasone (control group). In the isatuximab group, patients received intravenous isatuximab (10 mg/kg on days 1, 8, 15, and 22 of the first 28-day cycle, and days 1 and 15 of subsequent 28-day cycles). In both treatment groups, intravenous carfilzomib (20 mg/m2 on days 1 and 2 of the first cycle; and 56 mg/m2 on days 8, 9, 15, and 16 of the first cycle, and days 1, 2, 8, 9, 15, and 16 of subsequent cycles) and intravenous or oral dexamethasone (20 mg on days 1, 2, 8, 9, 15, 16, 22, and 23) were administered. The primary endpoint of the trial was progression-free survival, which was reported previously. Treatment continued until progression, unacceptable toxicity, or patient request to discontine. The overall survival analysis reported here was planned to be conducted 3 years after the primary progression-free survival analysis in the intention-to-treat population. Additional analyses were conducted on the secondary endpoints of time to next treatment and second-progression-free survival. Reported p values are non-inferential due to hierarchical testing. This trial is registered with ClinicalTrials.gov (NCT03275285). Findings Between Nov 15, 2017, and March 21, 2019, 302 patients were enrolled and randomly allocated: 179 (59%) to the isatuximab group and 123 (41%) to the control group. 169 (56%) patients were male, 133 (44%) were female, 214 (71%) were White, 50 (17%) were Asian, nine (3%) were Black or African American, and three (1%) were multiracial. At data cutoff for this overall survival analysis (Feb 7, 2023), 79 (44%) overall survival events in the isatuximab group and 59 (48%) in the control group had occurred (median follow-up 56&lt;middle dot&gt;61 months [IQR 54&lt;middle dot&gt;90-58&lt;middle dot&gt;02]). Median overall survival (in months) was not reached (NR; 95% CI 52&lt;middle dot&gt;17-NR) in the isatuximab group and was 50&lt;middle dot&gt;60 months (38&lt;middle dot&gt;93-NR) in the control group (hazard ratio [HR] 0&lt;middle dot&gt;855 [95% CI 0&lt;middle dot&gt;608-1&lt;middle dot&gt;202], nominal one-sided p=0&lt;middle dot&gt;18). Survival probability at 48 months was 59&lt;middle dot&gt;7% (95% CI 52&lt;middle dot&gt;0-66&lt;middle dot&gt;7) in the isatuximab group and 52&lt;middle dot&gt;2% (95% CI 42&lt;middle dot&gt;7-60&lt;middle dot&gt;8) in the control group (based on Kaplan-Meier analysis). Improvements in time to next treatment (HR 0&lt;middle dot&gt;583 [95% CI 0&lt;middle dot&gt;429-0&lt;middle dot&gt;792], nominal one-sided p=0&lt;middle dot&gt;0002) and second-progression-free survival (0&lt;middle dot&gt;663 [0&lt;middle dot&gt;491-0&lt;middle dot&gt;895], nominal one-sided p=0&lt;middle dot&gt;0035) were observed in the isatuximab group. The most common treatment- emergent adverse events were infusion reactions (82 [46%] patients in the isatuximab group and four [3%] in the control group) and upper respiratory tract infections (71 [40%] and 34 [28%], respectively). Discontinuations due to treatment-emergent adverse events were similar between treatment groups (24 [14%] in the isatuximab group and 22 [18%] in the control group), despite an additional 30 weeks of exposure in the isatuximab group. 12 (7%) patients in the isatuximab group and six (5%) patients in the control group had a treatment-related adverse event with a fatal outcome during study treatment. Interpretation At the time of the current analysis, a difference in overall survival could not be detected between the treatment groups, and no new safety signals were observed. Collectively, the evidence suggests that isatuximab plus carfilzomib-dexamethasone is a key treatment for patients with relapsed or refractory multiple myeloma. Funding Sanofi.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Lancet Haematology

ISSN

2352-3026

e-ISSN

—

Svazek periodika

11

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

10

Strana od-do

"e741"-"e750"

Kód UT WoS článku

001368600800001

EID výsledku v databázi Scopus

2-s2.0-85200910840